Larazotide Chemistry: The Tight-Junction Octapeptide
A bench-level reference sheet on Larazotide, a tight-junction-active octapeptide: how an eight-residue chain like this is built, how its identity is confirmed, and what to know before keeping one as a reference standard.
Sequence and Structure
Larazotide is a compact synthetic octapeptide, eight residues long, and that single number shapes most of how it is made, analyzed, and stored. It is a linear chain with no disulfide bridges, no cyclization, and no fatty-acid or other side-chain modification, so the molecule is essentially a short run of amino acids joined head to tail. That places it comfortably in the size range where modern solid-phase synthesis is routine rather than demanding.
The sequence is notably proline- and glycine-rich, a composition that gives the backbone a degree of flexibility and limits the ordered secondary structure a longer chain might adopt. For a research chemist the practical reading is that an eight-residue peptide carries few of the deletion and truncation complications that trouble long sequences, while the proline content is worth noting because it can influence coupling behavior during assembly and the shape of the chromatographic peak. Reading the composition off the sequence before any material is ordered is the same habit that applies across the research overviews in this library.
Origin and the Barrier-Modulating Family
Larazotide is a designed synthetic sequence rather than a fragment lifted directly from a natural protein. It is grouped among the barrier-modulating peptides, a small set of sequences studied for their activity at epithelial tight junctions, the protein complexes that seal the narrow space between adjacent cells. That classification is a chemistry label that tells a chemist where the peptide sits in the catalog, not a statement about any effect.
For a research chemist the family context is useful because barrier-modulating peptides tend to be short, single-chain, and unmodified, which means they respond well to the same synthetic and analytical methods. Treating Larazotide as one member of that group rather than as an isolated molecule makes it easier to anticipate how it will behave on the column and in the freezer. The same family-tree habit shown in our other research overviews applies here: knowing the class sets expectations before the material is ever in hand.
Synthesis by Fmoc Solid-Phase Peptide Synthesis
Larazotide is assembled by Fmoc solid-phase peptide synthesis, the same general method used across the reference catalog. The growing chain stays anchored to an insoluble resin while residues are added one at a time, from the C-terminus inward, each cycle removing the base-labile Fmoc protecting group and coupling the next protected amino acid before the chain is finally cleaved from the resin. At eight residues the assembly is a single linear build with no ligation step required.
Because the sequence is short and unmodified, Larazotide avoids the on-resin aggregation and difficult couplings that trouble long sequences, so it is a relatively clean target to make. The proline residues are the detail most worth watching, since proline couplings and the conformational kinks they introduce can occasionally slow a step and call for an optimized activator. For a fuller treatment of the underlying method, see our overview on Fmoc solid-phase synthesis; the principles there scale directly to an octapeptide like this one.
How Identity and Purity Are Confirmed
Identity and purity for Larazotide are established with the same two complementary tools used across the catalog. Reversed-phase HPLC separates the target octapeptide from any minor related species and reports purity as the proportion of total peak area attributable to the main peak, while mass spectrometry confirms identity by matching the measured mass to the value expected for the sequence. Read together, the two methods describe both how much of the sample is the intended peptide and whether that main peak is in fact the right molecule.
An eight-residue chain is a reasonably tidy analytical subject. There is limited scope for the long ladders of deletion sequences that complicate larger peptides, so the chromatogram is usually straightforward to read and the mass assignment unambiguous. The point of this section is the method rather than any single figure: these are the techniques used to characterize the chemistry, and the documentation for a given standard is the reference of record for that material.
Stability and Storage
As a lyophilized powder, Larazotide is comparatively stable when kept cold, dry, and out of light. Long-term storage of the dry solid is typically at freezer temperatures, with the container protected from moisture so the powder does not pick up water on opening. Allowing a sealed vial to reach room temperature before it is opened helps avoid condensation forming on the cold contents.
Once reconstituted, the working solution is far less forgiving. Peptides in solution are subject to hydrolysis, oxidation, and adsorption to surfaces, so reconstituted material is generally held cold and used within a short window, with freeze-thaw cycles minimized. The proline-rich backbone gives the chain a degree of flexibility but does not change these basics, which remain general handling principles for research peptides rather than claims about any one preparation. The documentation for a given standard should be the reference of record for its own conditions.
What Larazotide Is Studied For (Chemistry Only)
In a research-chemistry context, Larazotide is of interest as a small, well defined model peptide for barrier and tight-junction studies. Much of the laboratory literature that mentions it frames the sequence as a tight-junction-active peptide examined in epithelial cell and tissue models, where it serves as a defined, reproducible compound for that line of work. For the bench chemist it is also a convenient reference point when validating synthesis and analytical methods on other short, proline-rich sequences.
That framing is deliberately limited to the bench. Larazotide supplied as a reference standard is for laboratory research only, and nothing here describes or implies any human or veterinary use or outcome. Its value to a research chemist is as a chemistry subject: a compact, tractable octapeptide whose behavior under synthesis, analysis, and storage is easy to characterize and worth knowing in detail. For neighboring material, browse the rest of our research overviews for other compounds in the catalog.
This overview is provided for laboratory and research use only. It is educational chemistry reference material and is not for human or veterinary consumption. Buyers are responsible for compliance with all applicable laws and regulations.
What is Larazotide?
Larazotide is a small synthetic octapeptide, eight amino acids long, whose sequence is studied for its activity at epithelial tight junctions. It is a single linear chain with no disulfide bridges or side-chain modifications, which is why it is grouped as a barrier-modulating peptide. As a reference standard it is supplied as a lyophilized powder for laboratory research use only.
Why is Larazotide described as tight-junction-active?
The label is a chemistry classification, not a use claim. In the research literature Larazotide is studied at epithelial tight junctions, the protein complexes that seal the space between adjacent cells, which is why its sequence is described as tight-junction-active and the peptide is grouped as a barrier-modulating peptide. Here that term identifies the family the compound belongs to rather than any outcome.
How is Larazotide synthesized?
Larazotide is assembled by Fmoc solid-phase peptide synthesis. At eight residues it is a short, single-chain target built one amino acid at a time on a resin support, with the base-labile Fmoc group removed at each cycle before the next coupling and the chain cleaved at the end. Identity and purity are then confirmed by reversed-phase HPLC and mass spectrometry.
How should Larazotide be stored?
As a lyophilized powder, Larazotide is kept cold, dry, and out of light, with long-term storage of the dry solid typically at freezer temperatures. Reconstituted solution is far less stable and is generally held cold and used within a short window. Larazotide is a reference standard for research use only, not for human or veterinary use.